Karine (31), Henry (64) and
18 million people
have developed cancer
these last 12 months
Help us to answer this societal and human issue
Focus on cancer
Only 1 out of 4 patients used to survive cancer 50 years ago. Research has since improved our understanding of the disease and helped us to develop new therapies. Now, the survival rate is about 1 out of 2(*). While we have come a long way, there is still a long way to go.
(*) Cancer Research UK, 2020
The incidence of cancer will continue to rise due to factors such as ageing and the environment. By 2025, 1 out of 3 men and 1 out of 4 women (*) in developed countries will be diagnosed with cancer in their lifetime.
(*) www.frm.org, 2020
The earlier a cancer is diagnosed and treated, the higher the survival and complete remission rates will be. Anticipating the disease, making an early diagnosis and rolling out a targeted, personalised therapeutic arsenal are our best hope to save lives.
Research is crucial
Present therapies are the fruit of past research.
To beat cancer, we are constantly on the lookout for the most promising innovations
in order to bring them successfully from laboratory’s bench to patient’s bed.
Cancer research can be frustrating
Frustration as a patient
How can it be that we are still unable to cure all cancers after funnelling so many resources into research? Patients who face this insidious disease with many faces want effective and tolerable solutions… and they want them soon.
Frustration as a researcher
After patenting a discovery, a researcher needs to find new sources of funding. Not all researchers are natural-born entrepreneurs. Far too often, exciting projects end up floundering due to a lack of resources or unfamiliarity with the stages of development.
Frustration as a donor
What exactly will my donation be used for? What percentage of it goes towards covering operating expenses? How can I measure the impact of my donation? Are the projects making good progress? These legitimate concerns on donors’ minds sometimes go unanswered.
Our unique approach to fighting cancer
Following a careful selection of promising projects, we help laureates to make the leap to entrepreneurship and turn their discoveries into tangible solutions. As well as providing funds (up to 2.5 M€ per project), the Foundation puts them in touch with business administration experts and a multidisciplinary scientific network.
We keep our donors updated on how the projects are coming along with complete transparency. Our 100% model means that every last cent or penny donated goes to the projects.
Help us save lives
Karine (31) has ovarian cancer and Henry (64) has colorectal cancer. These two diseases are diagnosed each year in more than 580,000 * people in Europe. The Foundation is supporting a team that is developing an immunotherapy treatment for these two cancers in particular. The project has been named “Chasing the Clouds”.
Arthur’s dad has lung cancer. Ultra-targeted drugs could prove to be a promising therapeutic avenue. The Foundation has chosen to support a project aimed at developing a new generation of ADCs (Antibody Drug Conjugate) to fight several solid and liquid cancers. Their particularity comes from a cloak of invisibility that makes these drugs up to 10 x more effective.
(*) Globocan 2020 - Europe: colorectal cancer = 519,820 cas; ovarian cancer = 66,693 cases